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Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective
efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation
to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR
(Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system
during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent
M. tuberculosis infection. In silico analysis of the DosR regulon in BCG andM. tuberculosis showed at least 97%
amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different
BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to
that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant
TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens.
Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens
were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon
responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding
selected latency antigens. Since immune responses to TB latency antigens have been associated with control of
latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating
DosR regulon antigens to complement and improve the current BCG vaccine.
Tuberculosis (TB) remains a major global health threat.
Each year, about eight million new TB cases occur and two
million people die from TB. It is estimated that one-third of
the world population is latently infected with Mycobacterium
tuberculosis. From this vast latent reservoir, about 10% of in-
fected people are expected to develop overt TB disease during
their lifetimes. However, with the expanding human immuno-
deficiency virus type 1-AIDS pandemic, this number is ex-
pected to soar in the next few decades (11, http://www.who.int
/mediacentre/factsheets/fs104/en/).
The current TB vaccine is the live attenuated bacterium
Mycobacterium bovis Bacillus Calmette-Gue´rin (BCG). BCG is
known to protect against severe forms of TB in young children
and against leprosy. However, it does not efficiently and con-
sistently protect against pulmonary TB in adults, the most
prevalent and contagious form of TB; BCG also does not offer
protection from reactivation of latent TB infection. This partly
explains why BCG has little impact on the global TB epidemic
despite its widespread use as a prophylactic TB vaccine (http:
//www.who.int/wer/2004/en/wer7904.pdf). Over the years, many
hypotheses have been put forward to explain the apparent
variability in the protective efficacy of BCG, which varies from
0 to 80% (16). Explanations for this inconsistency include
differences in trial methodology, host population genetics, use
of different BCG vaccine strains (2), and heterogeneous
immunity to a variety of environmental mycobacteria that may
interfere with or mask the protection provided by BCG (7, 26).
Immune response profiles following BCG vaccination com-
prise myriad effector mechanisms, multiple T-cell subsets, and
many targeted antigens. BCG is capable of inducing Th1 re-
sponses (38), which are critical in mycobacterial infections
(17). In addition, BCG is also capable of inducing both CD4
and CD8 T-cell responses to antigens shared with M. tuber-
culosis, such as secreted antigens of the mycolyl transferase
family (Ag85) (19, 20, 33) and nondeleted members of the
ESAT-6 family (e.g., TB10.4) (32), but also heat shock proteins
like Hsp65 and Hsp70 (15). However, it is still not completely
known how these and other antigen-specific immune responses
contribute to protection against TB.
Recently we studied human T-cell responses to DosR
(Rv3133c) regulon-encoded antigens (referred to as TB la-
tency antigens) of M. tuberculosis (24). We observed preferen-
tial recognition of latency antigens by Mantoux skin test-pos-
itive individuals with latent TB compared to patients with TB
disease, suggesting that these immune responses are associated
with latent TB disease (13, 24). The DosR regulon is expressed
by tubercle bacilli under in vitro conditions of hypoxia and
* Corresponding author. Mailing address: Department of Immuno-
hematology and Blood Transfusion, Leiden University Medical Cen-
ter, Building 1, E3-Q, P.O. Box 9600, 2300 RC Leiden, The Nether-
lands. Phone: 31 71 526 5128. Fax: 31 71 526 5267. E-mail: t.h.m
.ottenhoff@lumc.nl.
† Present address: National Institute of Public Health and the En-
vironment, 3721 MA, Bilthoven, The Netherlands.
 Published ahead of print on 14 May 2007.
3523
low-dose nitric oxide exposure (40), and in gamma interferon
(IFN-)-activated macrophages (30). These conditions are
thought to mimic the environment encountered by tubercle
bacilli in vivo when persisting in immunocompetent hosts (31).
One of the most abundantly produced proteins during hyp-
oxia is the 16-kDa -crystallin homolog HspX (Rv2031c) (12).
HspX is one of the DosR-regulated genes and is targeted by
both CD4 T cells (9, 41) and CD8 T cells (10). Interestingly,
infants vaccinated with BCG do not mount immune responses
to HspX, whereas they are capable of generating immune
responses to other TB antigens (39). The absence of immune
responses to this particular latency antigen led us to the for-
mulation of our hypothesis. In this study, we tested the hypoth-
esis that BCG vaccination in humans and in a mouse model
fails to induce immune responses not only to HspX but gen-
erally to TB latency antigens that are targeted by the immune
system during latent M. tuberculosis infection.
MATERIALS AND METHODS
In vitro expression of the BCG DosR regulon. Expression of the DosR regulon
by M. tuberculosis strain H37Rv and 14 different BCG strains (Connaught JPG,
Pasteur 140, Sweden, Connaught, Japan, Canada, Vietnam, Danish SSI 1331,
Russian, Brazil, Tice, Moscow, Pasteur 133A, and Pasteur 1173; kindly provided
by Angelo Izzo, Colorado State University) was determined by using standard
methods of microarray RNA expression analysis as previously described (40).
Briefly, mycobacteria were grown in 7H9 medium (supplemented with bovine
serum albumin, NaCl, glucose, and glycerol) in 250-ml vented tissue culture
flasks with shaking at 90 rpm. At a culture optical density of 0.15, 30-ml cultures
were placed in an anaerobic GasPak chamber (Becton Dickinson & Company)
and shaking was continued. Reference cultures were treated in the same manner
but not placed in the anaerobic chamber. After 4 h, RNA was isolated and
microarray analysis was conducted as previously reported (40), with TB oligo-
nucleotide microarrays provided by Colorado State University through the Tu-
berculosis Vaccine Testing and Research Materials contract.
Study subjects. A cross-sectional study (The Netherlands) comprised 43
healthy adult persons (10 male, 33 female) who were vaccinated with BCG
between 1 and 37 years before this study (median time after vaccination, 25
years). The ages at the time of blood sampling ranged from 20 to 60 years.
Thirty-eight individuals were of Dutch origin; the remaining five individuals were
of German, British, Netherlands Antillean, Philippine, and South Korean de-
scent. After written informed consent was obtained, blood samples were ob-
tained from all study subjects by standard venous puncture and blood collection
in heparinized tubes. Subsequently, peripheral blood mononuclear cells (PBMC)
were isolated with a Ficoll density gradient and stored in liquid nitrogen as
described previously (24). The study protocol used (P207/99) was approved by
the ethical review board of the Leiden University Medical Center.
A longitudinal BCG vaccination study (United Kingdom) comprised adoles-
cents who were recruited through the United Kingdom schools’ BCG vaccination
program (4). Year 8 pupils (ages, 12 to 13 years) were informed of the study
verbally and by an information sheet, and recruitment proceeded after written
informed consent had been obtained from a parent or guardian and verbal
consent had been obtained from the child. Exclusion criteria were evidence of
previous BCG vaccination (BCG scar or vaccination records) or serious illness.
The ethnic backgrounds of participants were as follows: White British, 30%;
White Irish, 3%; Black Caribbean, 22%; Black African, 13%; Black other, 7%;
Asian Pakistan, 12%; Asian other, 5%; and mixed or other, 8%.
Ethical approval for this study was given by the Local Research Ethics Com-
mittee of Redbridge and Waltham Forest Health Authority and by the Ethics
Committee of the London School of Hygiene & Tropical Medicine.
Baseline blood samples were collected from participants at the time of tuber-
culin skin testing. Skin testing was carried out on the volar surface of the forearm
by the Heaf technique with tuberculin. A baseline 10 ml of intravenous blood was
taken and transferred into tubes containing 100 U of preservative-free sodium
heparin (Monoparin; CP Pharmaceuticals Ltd., Wrexham, United Kingdom).
Blood samples were set up in the whole-blood assay as soon as possible on the
same day as venipuncture. The Heaf test induration was inspected after 7 days
and graded appropriately by experienced nurses. Those due to receive BCG
following a negative Heaf test received BCG immediately (n  22). Two to 4
weeks following vaccination, depending upon school availability, recruits were
revisited for a follow-up 10-ml blood sample.
M. tuberculosis antigens. Recombinant proteins were produced as previously
described (18). Briefly, nucleotide sequences of selected M. tuberculosis H37Rv
genes were obtained from http://genolist.pasteur.fr/TubercuList. Genes were am-
plified by PCR from genomic DNA of M. tuberculosis H37Rv and cloned by
Gateway Technology (Invitrogen, San Diego, CA) in pDEST17, a bacterial
expression vector containing an N-terminal hexahistidine tag for rapid purifica-
tion with nickel-chelating resin. The proteins were overexpressed in Escherichia
coli BL21(DE3) and purified as previously described (18). Sequencing was per-
formed to confirm the identities of the cloned DNA fragments. Size and purity
were checked by gel electrophoresis and Western blotting with anti-His antibod-
ies (Invitrogen). Residual endotoxin levels were determined with a Limulus
amebocyte lysate assay (Cambrex) and were found to be below 50 IU/mg re-
combinant protein. Protein batches were subsequently tested for nonspecific
T-cell stimulation and for potential cellular toxicity in lymphocyte stimulation
assays with PBMC of non-M. tuberculosis-exposed, non-BCG-vaccinated, Man-
toux skin test-negative, healthy donors.
Lysate of M. tuberculosis grown under low-oxygen conditions was obtained
from M. tuberculosis H37Rv growing for 24 h in tubes with tightly screwed-on
caps as previously described (29). The low-oxygen-derived M. tuberculosis lysate
was kindly provided by Karen Weldingh and Peter Andersen (Statens Serum
Institute [SSI], Copenhagen, Denmark).
In vitro proliferation assays. Lymphocyte stimulation assays (cross-sectional
BCG vaccination study) were performed with isolated PBMC as previously
described (24). Briefly, PBMC (1.5  105/well) were cultured in Iscove’s modi-
fied Dulbecco modified Eagle medium (Gibco, Paisley, United Kingdom) sup-
plemented with 10% pooled human serum, 40 U/ml penicillin, and 40 g/ml
streptomycin in 96-well round-bottom microtiter plates (Nunc, Roskilde, Den-
mark) at 37°C in 5% CO2 in the absence or presence of stimulant. Antigens were
tested at the following concentrations: latency antigens, ESAT-6, CFP-10, and
Ag85B at 0.33 M; M. tuberculosis hypoxic lysate and purified protein derivative
(PPD) of M. tuberculosis (batch RT49 SSI, Denmark) at 5 g/ml; and positive
control phytohemagglutinin (PHA; Remel, United Kingdom) at 2 g/ml. The
total volume was 200 l/well. All stimulations were performed in triplicate. At
day 6, supernatants were harvested (75 l/well, pooled per triplicate) and stored
at maximally 20°C until use in the IFN- detection assay.
The diluted-whole-blood assay (longitudinal BCG vaccination study) was per-
formed as previously described (3). In summary, whole blood was diluted 1:5 with
serum-free medium (RPMI 1640 medium supplemented with 2 mM L-glutamine;
Invitrogen) and 100 l was plated in 96-well, round-bottom tissue culture plates
(Nunc, Roskilde, Denmark). Antigen was also added in 100 l to give a final
whole blood dilution of 1:10 and a culture volume of 200 l. Medium- and PHA
(5 g/ml; Sigma)-containing wells were included as negative and positive con-
trols, respectively, in parallel with the following M. tuberculosis antigens at 5
g/ml: PPD of M. tuberculosis (batch RT49, lot 210; SSI, Copenhagen, Den-
mark), Rv1733c, Rv2029c, Rv2623, Rv2627c, Rv2628, Ag85A, and the ESAT-6/
CFP10 fusion protein. Cell cultures were incubated on the day of blood collec-
tion at 37°C with 5% CO2. Supernatants were harvested on day 6 and stored at
maximally 20°C prior to enzyme-linked immunosorbent assay (ELISA).
Detection of IFN- by ELISA. (i) Cross-sectional study. IFN- concentrations
in supernatants were measured by ELISA (U-CyTech, Utrecht, The Nether-
lands). The detection limit of the assay was 20 pg/ml. ELISA samples were tested
in duplicate. The mean value of unstimulated cultures was subtracted from the
mean value of the stimulated cultures. A positive IFN- response was predefined
as 100 pg/m (24) in the cross-sectional study (The Netherlands). Positive in
vitro responses of the study subjects to the TB-specific antigens ESAT-6 and/or
CFP-10 were used as a marker of previous TB exposure (21, 37).
(ii) Longitudinal study. Quantitative IFN- ELISAs were done in single wells
(100 l) with commercially available antibody pairs (BD Pharmingen) as previ-
ously described (3). Recombinant IFN- (BD Pharmingen) was used for the
standard curve with a lower detection limit of 31 pg/ml. Negative control (me-
dium) values were subtracted from all results. A positive IFN- response was
predefined as 62 pg/ml (3) in this longitudinal study (United Kingdom). A
positive control supernatant was included in duplicate on each ELISA plate to
control for interplate and intraplate variations.
In vivo studies. BALB/c (H-2d) mice were bred at the Animal Facilities of the
WIV-Pasteur Institute of Brussels, from breeding couples originally obtained
from Bantin & Kingman (United Kingdom). All animals were 8 to 10 weeks old
at the start of the experiments. Experiments were performed in accordance with
the Ethical Committee of CODA-PIB-WIV regulations (permit no. 060202-02).
Male BALB/c mice were vaccinated with 0.2 mg (106 CFU) of a freshly
prepared solution of M. bovis BCG vaccine (strain GL2) grown as a surface
3524 LIN ET AL. INFECT. IMMUN.
pellicle on synthetic Sauton medium for 14 days and homogenized by ball mill
(22). Mice were immunized subcutaneously with 0.2 ml. Female BALB/c mice
were anesthetized with ketamine-xylazine and injected intramuscularly in both
quadriceps muscles with 2 50 g of the V1J.ns-tPA vector encoding the latency
antigen Rv1733c, Rv1738, Rv2029c, HspX (Rv2031c), Rv2032, Rv2626c,
Rv2627c, Rv2628, ESAT-6/CFP-10 fusion protein (21), or Ag85A (14, 28). Mice
were vaccinated three times at 3-week intervals, and immune responses were
analyzed 4 weeks after the third immunization.
BCG-vaccinated mice were sacrificed at 1 or 3 months after vaccination, and
their spleens were removed aseptically and homogenized with a loosely fitting
Dounce homogenizer. Plasmid DNA-vaccinated mice were sacrificed 4 weeks
after the third DNA immunization. Splenocytes (4  106 cells/ml) from three
mice per group were tested as a pool (month 1 after BCG) or individually (three
or four mice) (month 3 after BCG or after the last DNA vaccination) for a
cytokine response to purified recombinant His-tagged latency antigens, Ag85A,
or ESAT-6/CFP-10 (all at 5 g/ml). Pooled supernatants from at least three wells
were harvested after 72 h, when peak IFN- values can be measured, and stored
at 20°C until assayed. IFN- activity was quantified by sandwich ELISA with
coating antibody R4-6A2 and biotinylated detection antibody XMG1.2 (both
from Pharmingen). The assay sensitivity was 5 pg/ml. Samples were tested un-
diluted and at 1:10 and 1:100 dilutions. Cytokine content was calculated for the
dilution with an optical density value in the linear part of the standard curve.
Statistical analysis. For comparison of the proportion of responders between
test groups in the cross-sectional study, the chi-square (	2) test for independent
samples was used. However, Fisher’s exact test for independent samples was
applied if expected values were lower then or equal to 5 (E  5). Comparison of
the proportion of responders in the longitudinal study was performed by McNemar’s
test for paired samples. For all assays, P 
 0.05 was considered statistically
significant. For statistical analysis, SPSS 11.0 for Windows was used.
RESULTS
In silico sequence analysis and in vitro expression of the
DosR regulon of BCG. The DosR regulon of M. tuberculosis is
expressed in vitro under conditions of hypoxia and low-dose
nitric oxide stimulation (40). To evaluate whether BCG is
similarly capable of expressing the DosR regulon, we first as-
sessed available genome sequences of M. tuberculosis, M. bovis,
and BCG for the level of conservation and then performed in
vitro transcription profiling of DosR regulon-encoded genes.
Blast searches (http://ncbi.nlm.nih.gov/BLAST/) of DosR regu-
lon-encoded sequences showed that all 48 DosR regulon-en-
coded genes were highly conserved between M. tuberculosis
strains H37Rv and CDC1551 and M. bovis strains AF2122/97
and BCG Pasteur 1173P2. The homology of amino acid se-
quences was at least 97%, with 85% (41 of the 48) of the genes
being identical (data not shown).
Subsequently, we assessed the RNA expression profiles of 14
different BCG vaccine strains and M. tuberculosis H37Rv under
in vitro conditions of hypoxia and nitric oxide stimulation. The
results showed that all of the BCG strains tested have a func-
tional DosR regulon with an expression profile similar to that
of M. tuberculosis (40). Figure 1 shows the RNA profiles of
nine DosR-regulated genes of M. tuberculosis H37Rv and BCG
Pasteur strain 1173 when exposed to low oxygen levels. Selec-
tion of these nine genes was based on results from our previous
study (24), and the four most recognized latency antigens in
humans were included. These genes were further analyzed in this
study.
Immune responses to DosR regulon-encoded antigens in
human BCG vaccinees. Next we addressed the question of
whether BCG vaccination in human beings leads to the induc-
tion of immune responses to DosR regulon-encoded latency
antigens that are targeted during natural M. tuberculosis in-
fection.
IFN- responses to immunodominant latency antigens were
assessed in a longitudinal BCG vaccination study of young
adolescents in the United Kingdom. Twenty-two tuberculin
skin test-negative adolescents were included in the vaccination
group; blood was taken before and 2 to 4 weeks after BCG
vaccination. Results showed that responses to the latency an-
tigens of the participants before BCG vaccination were mini-
mal; the median responses to the latency antigens Rv1733c
Rv2029c, Rv2623, Rv2627c, and Rv2628 were below the pre-
defined cutoff level of 62 pg/ml IFN-, as used in this study
(Fig. 2A). BCG vaccination did not alter the response profiles
of the adolescents to the latency antigens; the proportion of
responders in the prevaccination group ranged from 4.5% to
33.3%, compared to 0% to 31.8% postvaccination with BCG.
Statistical analysis of the proportion of responders to TB la-
tency antigens showed no significant difference between pre-
and postvaccination with BCG (McNemar’s test, P  0.500 to
P  1.000).
Following BCG vaccination, there was a significant increase
in the IFN- response to PPD, from 46% to 96% responders
(P  0.001). There was no significant difference for responses
to Ag85A, only a trend toward an increase in response, from
64% to 77% responders (P  0.375). Although all of the
eligible subjects tested negative in the tuberculin skin test
(Heaf test) prior to BCG vaccination, in vitro stimulation with
PPD or Ag85A showed that a considerable proportion of the
adolescents tested gave positive whole-blood assays (46% and
64%, respectively), most likely as a result of exposure to cross-
reactive environmental mycobacteria. As expected, none of the
participants responded to the M. tuberculosis-specific ESAT-6/
CFP-10 fusion protein (Fig. 2B). Thus, these results show that
in adolescents following BCG vaccination virtually no in-
creases in responses to M. tuberculosis latency antigens are
observed.
Next, we carried out a cross-sectional study (The Nether-
lands) including BCG-vaccinated adults without exposure to
TB (n  27) compared to subjects with likely exposure to TB
(n  16). For this study, individuals with an IFN- response of
100 pg/ml to M. tuberculosis-specific antigens ESAT-6 and
CFP-10 (21, 37) were considered previously exposed to TB.
FIG. 1. Expression of DosR genes (RNA). RNA transcript expres-
sion profiles (fold induction) of nine DosR-encoding genes induced
under low-oxygen conditions in M. tuberculosis H37Rv (n  4) and
BCG Pasteur 1173 (n  4). The RNA expression profiles of both
strains are highly similar, except for that of Rv1738. Data are shown as
the mean plus the standard deviation.
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Figure 3 shows the immune recognition profiles of both
BCG-vaccinated groups to the latency antigens. Overall, BCG-
vaccinated individuals without evidence of exposure to TB
showed significantly lower production of IFN- in response to
the latency antigens than did the group that had positive re-
sponses to ESAT-6 and/or CFP-10; the median IFN- re-
sponses to all of the latency antigens tested in the unexposed
group were all below the cutoff level of 100 pg/ml, whereas the
FIG. 2. IFN- responses to M. tuberculosis latency antigens in a longitudinal BCG study. Box-and-whisker plots of IFN- responses to the
latency antigens in schoolchildren pre- and postvaccination with BCG are shown. The horizontal black line in the box represents the median, the
lower boundary of the box represents the 25th percentile, and upper boundary represents the 75th percentile. Whiskers extend from the box to
the highest and lowest values with exclusion of the extreme values and the outlier values. Supernatants were taken after 6 days for measurement
of IFN- production. (A) IFN- responses of the pre-BCG-vaccination group to the latency antigens tested. (B) Responses to PHA and control
antigens PPD, Ag85A, and the ESAT-6/CFP-10 fusion protein (E/C FP). Vaccinated adolescents, n  22, except for antigen Rv1733c in the
prevaccinated group, where 12 individuals were tested. An IFN- response of 62.5 pg/ml was considered positive. The McNemar test for paired
samples was used to compare the proportions of responders per group (, P  0.001).
FIG. 3. IFN- responses to M. tuberculosis latency antigens in a cross-sectional BCG study. Box-and-whisker plots of IFN- responses to the latency
antigens by BCG-vaccinated individuals are shown. The horizontal black line in the box represents the median, the lower boundary of the box represents
the 25th percentile, and the upper boundary represents the 75th percentile. Whiskers extend from the box to the highest and lowest values, with exclusion
of the extreme values and the outlier values. Supernatants were taken after 6 days for measurement of IFN- production. (A) IFN- responses to the
latency antigens of the group that was BCG vaccinated without TB exposure (no IFN- production in response to ESAT-6 or CFP-10) or with exposure
to TB (positive IFN- production in response to ESAT-6 or CFP-10). (B) IFN- responses to control stimuli PHA, PPD, MTB, Ag85B, ESAT-6, and
CFP-10. MTB, lysate of M. tuberculosis cultured under low-oxygen conditions. BCG-vaccinated group without TB exposure, n  23, BCG-vaccinated
group with TB exposure, n  16. An IFN- response of 100 pg/ml was considered positive. 	2 test: , P 
 0.05; , P 
 0.01. †, Fisher’s exact test.
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opposite was true of the TB-exposed group. In the latter group,
the median IFN- values in response to all of the latency
antigens tested, except protein Rv2628, were above 100 pg/ml,
indicating that more than half of the individuals strongly rec-
ognized the antigens (Fig. 3A). The proportions of responders
(i.e., 100 pg/ml IFN-) per antigen were as follows (BCG
vaccinated without TB exposure versus BCG vaccinated with
TB exposure): Rv1733c, 44.4% versus 93.8% (P  0.001);
Rv2029c, 37.0% versus 81.3% (P  0.005); HspX, 22.2% ver-
sus 56.3% (P  0.024); Rv2032, 29.6% versus 68.8% (P 
0.013); Rv2626c, 20.0% versus 68.8% (P  0.003); Rv2627c,
25.9% versus 75% (P  0.002); Rv2628, 25.9% versus 43.8%
(P  0.228). Furthermore, the levels of IFN- production in
the BCG-vaccinated group with suspected TB exposure were
similar to those we previously found in Mantoux-positive indi-
viduals (24). In addition to the responses to latency antigens,
exposure to TB was also associated with higher IFN- produc-
tion in response to Ag85B (P  0.005), which is shared be-
tween BCG and M. tuberculosis. The data also suggest that the
responses to mycobacterial complex antigens like PPD (P 
0.139) and M. tuberculosis lysate (from bacteria cultured under
hypoxic conditions) (P  0.279) are higher, but no significant
difference was detected (Fig. 3B).
Time after BCG vaccination and moment of sampling varied
considerably in our study population. We therefore attempted
to seek a correlation between the level of IFN- production
and time since vaccination. However, no time-dependent as-
sociation was observed (data not shown).
Taken together, BCG vaccination of the skin, in general, ap-
pears to induce poor responses not only to HspX but also to other
latency antigens ofM. tuberculosis. In contrast, following exposure
to TB, significant responses to latency antigens are seen.
Immune responses to DosR regulon antigens in mice. In
order to determine whether BCG vaccination also fails to
induce adequate T-cell responses to M. tuberculosis latency
antigens in mice, BALB/c mice were vaccinated subcutane-
ously with BCG (n  3). The mice were sacrificed 4 weeks and
3 months after BCG vaccination in order to test splenocytes for
IFN- production in response to latency antigens, the homol-
ogous or shared mycobacterial antigen Ag85A, and the ESAT-
6/CFP-10 fusion protein of M. tuberculosis (21). Four weeks
postvaccination with BCG, splenocytes showed very low to no
production of IFN- when stimulated with latency antigens
(Fig. 4B). The levels of IFN- were low, similar to those of
naive control mice (Fig. 4A). At this same time point, cells
produced significant amounts of IFN- in response to Ag85A
FIG. 4. IFN- responses to M. tuberculosis latency antigens in BALB/c mice following subcutaneous or intramuscular BCG vaccination with
plasmid DNA. Supernatants were taken after 3 days (72 h) for measurement of IFN- production. (A) Naive, non-BCG-vaccinated mice tested
as a pool (n  3). (B) Mice at 4 weeks postvaccination with BCG, tested as a pool (n  3). (C) Mice at 3 months postvaccination with BCG (n 
3). (D) Mice were immunized three times with plasmid DNA encoding one of the eight latency antigens, Ag85A, or ESAT-6/CFP-10. Splenocytes
were restimulated in vitro with their respective antigens (n  4).
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(Fig. 4B) and PPD (data not shown). As expected, responses to
the fusion protein ESAT-6/CFP-10 were absent. When re-
sponses were assessed at 3 months postimmunization, similar
results were obtained: IFN- responses of splenocytes of vac-
cinated mice to latency antigens remained at levels comparable
to those of naive mice (Fig. 4A), and significant IFN- pro-
duction was found only in response to Ag85A (Fig. 4C). To
rule out the possibility that the absence of IFN- response to
latency antigens was due to an inherent inability of BALB/c
mice to respond to these latency antigens, mice were vacci-
nated with DNA. BALB/c mice (n  4) were vaccinated three
times at 3-week intervals with naked plasmid DNA encoding
one of eight different latency antigens, Ag85A, or ESAT-6/
CFP-10. Four weeks after the last immunization, spleen cell
IFN- production was analyzed. Vaccination with six out of
eight of these plasmids induced significant antigen-specific
IFN- production (Fig. 4D). Robust levels of IFN- were pro-
duced after in vitro restimulation with Rv1733c, HspX,
Rv2032c, Rv2626c, Rv2627c, and Rv2628. Antigens Rv1738
and Rv2029c appeared to be not very immunogenic for T cells
in BALB/c mice, although significant antibody responses to the
latter protein could be induced (29a). Vaccination with plas-
mid DNA encoding Ag85A or the ESAT-6/CFP-10 fusion pro-
tein was also very effective at inducing a strong IFN- re-
sponse. The results thus demonstrate that mice are able to
generate strong Th1-type immune responses to latency anti-
gens after immunization with plasmid DNA but that subcuta-
neous BCG administration fails to induce immune responses
to M. tuberculosis latency antigens in BALB/c mice.
DISCUSSION
Relatively little is known about the antigen specificity of
immune response profiles following BCG vaccination in rela-
tion to protection against TB. In this study, we addressed the
question of whether BCG vaccination induces immune re-
sponses to DosR regulon-encoded antigens, in particular, to
those TB latency antigens that are targeted during persistent
M. tuberculosis infection (24).
Comparison of available genome sequences of M. tubercu-
losis, M. bovis, and BCG showed that the entire set of DosR
regulon coding sequences is conserved in BCG; except for a
few minor point mutations, which are not expected to have a
major impact on the expression or immunologic recognition of
these antigens. Subsequently, transcriptional analysis of 14 dif-
ferent BCG vaccine strains under in vitro conditions of low
oxygen and nitric oxide exposure were studied. Our results
show that RNA expression profiles of the DosR regulon la-
tency antigens reported in this study were highly similar to
those previously reported for M. tuberculosis (40). In addition,
BCG is reported to be capable of adapting to anaerobiosis in
vitro by shifting down to a nonreplicating persistent state, sim-
ilar to M. tuberculosis (25). When tested in the so-called Wayne
model or in standing (i.e., hypoxic) cultures, it was previously
shown that BCG is capable of producing at least four DosR
regulon-encoded proteins, Rv2623, Rv2626c, HspX (Rv2031c,
acr), and DosR (Rv3133c) (5, 6). We conclude from these in
vitro observations that BCG has a functional DosR regulon,
although no complete proteomic data are available to demon-
strate that every single protein encoded by the regulon is indeed
expressed.
Next we monitored immune responses to a series of immu-
nodominant TB latency antigens following BCG vaccination,
in both longitudinal and cross-sectional studies with two dif-
ferent human cohorts, and corroborated our findings in a
BALB/c mouse model.
As mentioned before, neonates vaccinated with BCG at
birth do not develop an immune response to the latency anti-
gen HspX, whereas they are capable of mounting responses to
other non-dormancy-associated TB antigens (including PPD)
(39). BCG-vaccinated adolescents (longitudinal study) and
BCG-vaccinated adults who had not been exposed to TB (i.e.,
in vitro negative for production of IFN- in response to
ESAT-6 and/or CFP-10) (cross-sectional study) mounted im-
mune responses to secreted antigens of the Ag85 complex and
PPD but did not develop a response to HspX or any of the
other latency antigens tested (Fig. 2 and 3).
In contrast to the results described above, BCG-vaccinated
adults with previous exposure to TB (i.e., in vitro positive
production of IFN- in response to ESAT-6 and/or CFP-10) in
the cross-sectional study showed significantly higher IFN-
responses to selected TB latency antigens next to increased
and significant (only Ag85B) responses to common TB anti-
gens. These results agree with our recent findings that T cells
from individuals with latent TB infection preferentially recog-
nize a set of TB latency antigens (i.e., Rv1733c, Rv2029c, and
Rv2627c) while patients with (past or active) TB disease pref-
erentially recognize secreted antigens such as CFP-10 and
ESAT-6 (13, 24).
The absence of detectable in vitro responses to M. tubercu-
losis latency antigens in BCG-vaccinated adults may, in part, be
explained by the common belief that BCG-induced protection
against TB wanes over a period of 10 to 15 years (34). Since
time after BCG vaccination in our study group varied between
1 and 37 years, we attempted to correlate the level of responses
to latency antigens with the time elapsed since vaccination but
found no significant association.
Somewhat unexpectedly, 46% of the adolescents who tested
negative in the Heaf skin test prior to BCG vaccination showed
in vitro responses to PPD. Our own observations (unpub-
lished) and those of others (4) show that in vitro detectable
immune responses to PPD can be observed in a significant
group of Mantoux-negative, non-BCG-vaccinated, non-TB-ex-
posed, healthy individuals. This phenomenon is likely caused
by previous exposure to cross-reactive environmental myco-
bacteria (4, 7, 16, 26). In addition, previous exposure to envi-
ronmental mycobacteria might also have induced low-level re-
sponses (4.5% to 33% responders) in the prevaccinated BCG
group in the longitudinal study (Fig. 2) since DosR regulon-
encoded antigens have not been reported to be solely ex-
pressed in M. tuberculosis.
Our findings on humans were corroborated with BCG-vac-
cinated BALB/c mice. Upon subcutaneous vaccination with
BCG, the mice generated immune responses to the common
M. tuberculosis antigens Ag85A and PPD. In contrast, poor
responses were detectable against M. tuberculosis latency anti-
gens both 1 and 3 months postvaccination. Yet, vaccination
with recombinant plasmid DNAs induced a strong T-cell re-
sponse to several latency antigens, including Rv1733c, HspX,
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Rv2032, Rv2626c, Rv2627c, and Rv2628, as well as Ag85A and
the ESAT-6/CFP-10 fusion protein. Plasmid DNAs encoding
Rv1738 and Rv2029c were not immunogenic in mice. This
demonstrated that the mice were able to generate strong Th1-
type immune responses to M. tuberculosis latency antigens
when immunized with plasmid DNAs but that subcutaneous
BCG administration failed to induce immune responses to
such antigens in BALB/c mice. With HLA-transgenic mice (19,
20), a similar observation concerning HspX was recently made
in our laboratory; mice vaccinated with BCG did not develop
immune responses to HspX, whereas immunization with HspX
did induce responses to HspX and its predefined T-cell
epitopes (10, 20a).
Of interest is our observation that the recognition patterns
of latency antigens seem to be different between humans and
BALB/c mice. It appears that humans responded most strongly
to antigens Rv1733c, Rv2029c, and Rv2627c, whereas mice
responded most strongly to Rv1733c, Rv2032, and Rv2626c
(although both were not statistically significant). However, this
may be related to the different modes of antigen exposure, i.e.,
natural infection of humans versus DNA vaccination of mice.
This observation might have implications for proof-of-concept
studies which involve TB latency antigens in mouse models and
their extrapolation to latent TB in humans.
Finally, two other animal models confirmed the lack of T-
cell responses to M. tuberculosis latency antigens following
BCG vaccination. First, adult male rhesus monkeys were vac-
cinated with BCG (23) and in vitro immune responses to M.
tuberculosis latency antigens were monitored at 9 weeks post-
vaccination. Similar to observations on humans and mice, sig-
nificant immune responses to PPD were seen following BCG
vaccination but responses to M. tuberculosis latency antigens
were not (F. Verreck, personal communication). Second, cattle
were vaccinated with BCG or infected with M. bovis (8) and
immune responses to a series of latency antigens, (bovine)
PPD, and the ESAT-6/CFP-10 fusion protein were measured.
Significant responses to PPD were observed, and animals in-
fected with virulent M. bovis also responded significantly to
ESAT-6 and CFP-10, but no significant responses to any of the
latency antigens tested were observed (M. Denis and B.
Buddle, personal communication). Although it is difficult to
establish positive controls for responses to TB latency antigens
in these two animal models, the results are likely accounted for
by the same mechanisms underlying the effects observed in
humans and mice following BCG vaccination.
The studies summarized above were performed with differ-
ent strains of BCG, and this may potentially confound the
interpretation and comparison of results. However, microarray
expression profiling of 14 different BCG vaccine strains showed
highly similar regulation of the DosR regulon. This rather sug-
gests that lack of immune responses to TB latency antigens fol-
lowing BCG vaccination is not a strain-specific phenomenon but
an intrinsic property of dermal vaccination with BCG.
Upon administration to the skin, BCG is ordinarily not ex-
pected to persist in immunocompetent humans, although rare
cases of persistence and reactivation of BCG have been re-
ported in individuals who developed immune deficiencies
many years after vaccination (1, 27, 35, 36). It therefore seems
unlikely that BCG in the skin will encounter the necessary
environmental triggers needed to express the latency antigens
and subsequently to trigger immune responses. Moreover, the
absence of T-cell responses is not due to restrictions in the
T-cell repertoire since mice respond to these antigens when
immunized with plasmid DNAs and BCG-vaccinated individ-
uals exposed to TB also respond to latency antigens by IFN-
production. Further studies will be aimed at the identification
of the exact mechanisms responsible for the regulation and
expression of the DosR regulon and immunity to latency an-
tigens following BCG vaccination.
Since the start of its first use in the 1920s, three billion doses
of BCG have been delivered throughout the world, unfortu-
nately with relatively little impact on the global TB epidemic,
underlining the need for a better vaccine regimen. Our findings
suggest future studies evaluating the protective efficacy of la-
tency antigens against (latent) TB and potential use of latency
antigens as vaccine candidates, either alone, with BCG, or as
postexposure TB vaccines.
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